•  
  •  
 

Abstract

Introduction. The condition of neutropenia increases the risk of infection. The causes of neutropenia are widely discussed as side effects of chemotherapy, but patients with neutropenia who are not due to side effects of chemotherapy are increasing in number. This study aims to provide an overview of the characteristics of neutropenic fever population unrelated to chemotherapy. Method. The study was conducted retrospectively on the medical records of neutropenic fever patients who were not chemotherapy-related in the National Hospital Dr. Cipto Mangunkusumo in January 2018-November 2019. Variables studied included demographic, clinical characteristics, classification of multinational association of supportive care in cancer (MASCC) scores and their etiology, and mortality outcomes within 5 days of treatment. Results. Total of 68 subjects were included in this study, consist of 50% female and 50% male with median age was 38.5 years (interquartile range 27). Diagnosis data showed that 86.8% subjects were patients with hematological abnormalities, 3 patients had solid tumors (lymphoma, colon cancer and lung cancer), and the rest were non-malignant diseases. Analysis showed that 72.1% onset of fever was found in outpatient care, the rest was inpatient care. The mean value of absolute neutrophil count was 201.50 (SD 173.18), meanwhile the mean MASCC score was 21 (SD 4.54) in the low-risk category. A total of 35 subjects (51.5%) had a MASCC low risk score and 33 subjects (48.5%) had a high risk. The median procalcitonin subject was 1.99 ng / mL (range 0.11 - 178.30). The 5-days mortality incidence was 54.4%. Chi-square analysis of the two groups found significant differences in care mortality (p <0.05). Analysis with Independent T-test also showed a significant differences in the parameters of age and systolic blood pressure values between the high risk and low risk groups. Conclusions. The majority etiologies among subjects were haematological disorders. Based on the MASCC score, most of the subjects were in the high-risk group. Total of mortality incidence was 54.4%.

References

1. Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs. 2011;26(10):1054–60. 2. Andrès E, Mourot-Cottet R, Maloisel F, Keller O, Vogel T, Séverac F, et al. History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs. J Clin Med. 2017;6(10):92. 3. Andrès E, Mourot-Cottet R. Non-chemotherapy drug-induced neutropenia - an update. Expert Opin Drug Saf. 2017;16(11):1235– 42. 4. Bodey GP. Fever and neutropenia: The early years. J Antimicrob Chemother. 2009;63(suppl 1):3–13. 5. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, twocenter validation of a prediction rule. J Clin Oncol. 1992;10(2):316– 22. 6. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51. 7. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela J, Antonio M, Font C, Biosca M et al. SCWG of the SS of MO (SEOM). Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors. Clin Transl Oncol. 2017;19:386–95. 8. O’Neal R, Roberts K, Chen Q, Huang B, Saeed H, Ramlal R, et al. Applications for the MASCC Risk Index for Febrile Neutropenia in Patients with Hematologic Malignancy. Biol Blood Marrow Transplant. 2019;25(3):S131–2. 9. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27:v111–8. 10. Koivula I, Inen S, Jantunen ESA, Pulkki K, Kuittinen T, Nousiainen T, et al. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis. 2011;43(6-7):471-8. 11. Andrès E, Maloisel F, Kurtz JE, Kaltenbach G, Alt M, Weber JC, et al. Modern management of non-chemotherapy drug-induced agranulocytosis: A monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med. 2002;13(5):324–8 12. Baskaran ND, Gan GG, Adeeba K. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol. 2008;87(7):563–9. 13. Ortega M, Rovira M, Filella X, Almela M, De La Bellacasa JP, Carreras E, et al. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol. 2004;126(3):372–6. 14. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The Role of Procalcitonin in Febrile Neutropenic Patients : Review of the Literature. Infection. 2008;(5):396–407. 15. Paesmans M, Klastersky J, Maertens J, Georgala A. Predicting febrile neutropenic patients at low risk using the MASCC score : does bacteremia matter? Support Care Cancer. 2011;19:1001–8. 16. Kim M, Ahn S, Kim WY, Sohn CH, Seo DW, Lee YS, et al. Predictive performance of the quick Sequential Organ Failure Assessment score as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia. Support Care Cancer. 2017;25(5):1557–62. 17. Uys A, Rapoport BL, Fickl H, Meyer PWA. Prediction of outcome in cancer patients with febrile neutropenia : comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin , C-reactive protein , serum amyloid A , and. Eur J Cancer Care (Engl). 2007;16:475–83. 18. Guadiana-Romualdo LG de, Cerezuela-Fuentes P, Español-Morales I, Esteban-Torrella P, Jiménez-Santos E, Hernando-Holgado A, et al. Prognostic value and Procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy associated febrile neutropenia presenting to an amergency departement. Biochem Med. 2019;29(1):1–11. 19. Giamarellos‐Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H. Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile Neutropenia. Clin Infect Dis. 2001;32(12):1718–25

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.